This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E26.8 (other hyperaldosteronism) | Special Copayment Reduction: V254 (rare disease; 10% copayment for 5 years after registration) |
| B. Synonyms | Bartter syndrome, Salt-wasting tubulopathy, Hyperprostaglandin E syndrome (HPS), renal tubulopathy with hypokalemic alkalosis, Bartter syndrome type I–V |
| C. Adult onset | Likelihood of first presentation in adulthood low (possible in some) — most present in the fetal period (polyhydramnios) or in the neonatal period to childhood. However, milder subtypes overlapping with Gitelman syndrome (Type III, IV) are sometimes found incidentally in adulthood. |
| 1. History | First description by Frederic Bartter in 1962 → triad of hypokalemia, metabolic alkalosis, and normal blood pressure → identification of the SLC12A1 and KCNJ1 genes in the 1990s → establishment of the five-genotype (Type I–V) system. |
| 2. Causes | Deficiency of genes for ion channels/transporters involved in NaCl reabsorption in the thick ascending limb of the loop of Henle (TAL); Type I: NKCC2 (SLC12A1), Type II: ROMK (KCNJ1), Type III: CLC-Kb (CLCNKB), Type IV: Barttin (BSND), Type V: CaSR (CASR). |
| 3. Genetics | Mainly autosomal recessive (Type I–IV); Type V is autosomal dominant (CASR activating variants); 5 genes (SLC12A1, KCNJ1, CLCNKB, BSND, CASR); clear genotype-phenotype correlation. |
| 4. General epidemiology | Incidence 1:50,000–100,000; a small number of cases worldwide, including Korea; timing of onset differs by type (neonatal vs. classic); equal occurrence in males and females. |
| 5. Pathophysiology | Impaired NaCl reabsorption in the TAL → hyponatremia, hypokalemia, metabolic alkalosis → overstimulation of renin-aldosterone → systemic vasodilation → blood pressure maintained at normal; prostaglandin E2 excess contributes to worsening of symptoms. |
| 6. Symptoms | Neonatal type: severe dehydration, polyuria, failure to thrive; classic type: failure to thrive, muscle weakness, cramps, polydipsia and polyuria; common: symptoms of hypokalemia (muscle weakness, constipation, fatigue). |
| 7. Signs | Serum hypokalemia, hypochloremia, metabolic alkalosis; normal blood pressure; elevated plasma renin and aldosterone; elevated urinary potassium; nephrocalcinosis (Type I, II). |
| 8. Screening | Prenatal: suspect when polyhydramnios + fetal polyuria are found; after birth: neonatal dehydration and polyuria + electrolyte abnormalities → immediate differentiation; prenatal genetic diagnosis possible if there is a family history. |
| 9. Diagnosis | Serum electrolytes and HCO₃⁻; plasma renin and aldosterone; urine electrolytes (FEK, FECl); urine Ca/Cr; PGE2 metabolites; renal ultrasound (calcification); genetic testing (SLC12A1, KCNJ1, CLCNKB, BSND, CASR panel). |
| 10. Treatment | Potassium and magnesium supplementation; indomethacin (prostaglandin synthesis inhibition, key in Type I/II); RAAS blockade (spironolactone, ACE inhibitors); potassium-sparing diuretics; hearing aids and kidney transplantation in Type IV. |
| 11. Prognosis | Risk of failure to thrive and renal failure if untreated; near-normal growth possible with appropriate treatment; high risk of progression to renal failure in Type IV; long-term follow-up related to overall quality of life needed. |
| 12. Prevention | Genetic counseling; prenatal diagnosis; early diagnosis and appropriate electrolyte supplementation; monitoring for complications of long-term NSAID use; regular follow-up of nephrocalcinosis and renal function. |
| 13. References | Bartter FC et al. Hyperplasia of the juxtaglomerular complex … and 9 other papers |
The history of Bartter syndrome begins with a report of two cases published in the American Journal of Medicine in 1962 by Frederic Crosby Bartter, an endocrinologist at the US National Institutes of Health (NIH), and his colleague William Pronove. They described two patients with hypokalemia, metabolic alkalosis, and elevated plasma renin and aldosterone, but nonetheless normal blood pressure. This finding at the time directly challenged the existing concept that aldosterone excess is always accompanied by hypertension.
Bartter first proposed the hypothesis that, in the pathophysiology of this syndrome, overactivation of the renin-angiotensin-aldosterone system (RAAS) is combined with vascular resistance to angiotensin II, so blood pressure does not rise. Later, in the 1970s, it was established that prostaglandins (especially PGE2) are overproduced in this syndrome and contribute to vasodilation and RAAS stimulation. In particular, in 1976 Gill et al. first used indomethacin (a prostaglandin synthesis inhibitor) to treat Bartter syndrome and reported dramatic symptom improvement, confirming that prostaglandin excess is a key part of the pathophysiology. Accordingly, neonatal Bartter syndrome was also called "hyperprostaglandin E syndrome (HPS)".
The 1990s were the period when the molecular basis of Bartter syndrome was elucidated. In 1996, Simon et al. published in Nature Genetics that deficiency of the SLC12A1 gene encoding the NKCC2 transporter (Type I) and of the KCNJ1 gene encoding the ROMK potassium channel (Type II) causes Bartter syndrome. Subsequently, Simon et al. in 1997 identified deficiency of CLCNKB (CLC-Kb chloride channel, Type III), and Birkenhäger et al. in 2001 identified deficiency of BSND (Barttin, Type IV). Most recently, in 2006, Vezzoli et al. reported that activating variants of the CASR gene encoding the calcium-sensing receptor cause Type V Bartter syndrome.
In Korea, case reports of Bartter syndrome have been made in pediatrics and nephrology since the 1990s, and genetically confirmed cases have been increasing since the 2000s. In the guidelines of the Korean Society of Pediatric Nephrology and the Korean Society of Nephrology, Bartter syndrome is treated as an important pediatric tubular disease, and it is designated as eligible for registration under rare disease Special Copayment Reduction V254.
Gitelman syndrome, which is similar to but distinct from Bartter syndrome, was first described by Hillel Jonathan Gitelman in 1966 and was identified in 1996 as caused by deficiency of the SLC12A3 gene (NCCT, the NaCl cotransporter of the distal convoluted tubule). Gitelman syndrome tends to be milder than Bartter syndrome and to present in adulthood, and is characteristically distinguished by hypomagnesemia and hypocalciuria. Because the two diseases overlap clinically, accurate genetic analysis is essential for differential diagnosis.
Bartter syndrome is caused by pathogenic variants in genes encoding ion channel or transporter proteins involved in NaCl reabsorption in the thick ascending limb of the loop of Henle (TAL) of the renal tubule. To date, five genotypes (Type I–V) have been identified.
Type I — NKCC2 deficiency (SLC12A1 gene)
Autosomal recessive variants of the SLC12A1 gene (15q21.1) encoding the sodium-potassium-2-chloride cotransporter 2 (NKCC2) located in the apical membrane of the TAL. NKCC2 is the key transporter that carries 1Na⁺:1K⁺:2Cl⁻ into the cell in the TAL. It causes severe neonatal Bartter syndrome (antenatal/neonatal type), characterized by polyhydramnios, extreme polyuria, and nephrocalcinosis.
Type II — ROMK deficiency (KCNJ1 gene)
Autosomal recessive variants of the KCNJ1 gene (11q24.3) encoding the inwardly rectifying potassium channel (ROMK, renal outer medullary potassium channel) located in the apical membrane of the TAL. ROMK is essential for maintaining NKCC2 function by recycling K⁺ absorbed via NKCC2 back into the lumen. Like Type I, it causes a severe neonatal type, but because ROMK is also involved in potassium secretion in the collecting duct, transient neonatal hyperkalemia may characteristically occur.
Type III — CLC-Kb deficiency (CLCNKB gene)
Autosomal recessive variants of the CLCNKB gene (1p36.13) encoding chloride channel Kb (CLC-Kb) located in the basolateral membrane of the TAL and distal convoluted tubule (DCT). Unlike Types I and II, it is the classic type (classic Bartter syndrome), with variable timing of onset (neonatal period to adulthood) and relatively mild symptoms. Large deletions between this gene and the adjacent similar gene CLCNKA (CLC-Ka) can result in deficiency of both channels.
Type IV — Barttin deficiency (BSND gene)
Autosomal recessive variants of the BSND gene (1p32.3) encoding Barttin, the β-subunit of the CLC-Ka and CLC-Kb chloride channels. Barttin is expressed not only in the kidney but also in the stria vascularis of the inner ear, where it is involved in endolymph formation, so Type IV is characterized by severe neonatal Bartter syndrome accompanied by sensorineural hearing loss. Renal function decline is more severe than in other types, and it often progresses to end-stage renal failure.
Type V — CaSR activating variants (CASR gene)
Activating (gain-of-function) variants of the CASR gene (3q21.1) encoding the calcium-sensing receptor (CaSR). Autosomal dominant inheritance. The activated CaSR inhibits NKCC2 activity in the TAL, reducing NaCl reabsorption. It is characteristically accompanied by hypocalcemia and hypocalciuria (hypoparathyroidism phenotype), distinguishing it from other types of Bartter syndrome.
Bartter syndrome Types I–IV follow an autosomal recessive inheritance pattern, and when both parents are carriers, on average 1 in 4 children is affected. Only Type V is autosomal dominant, in which a single activating variant alone is enough for the phenotype to be expressed.
Type I (SLC12A1, OMIM #601678): long arm of chromosome 15 (15q21.1). 26 exons. More than 60 pathogenic variants reported, including missense, nonsense, splicing, and large deletions. Founder effects reported in certain populations (some Arab populations).
Type II (KCNJ1, OMIM #241200): long arm of chromosome 11 (11q24.3). Uniquely, a paradoxical finding of transient hyperkalemia occurs in the neonatal period, due to suppression of K⁺ secretion via ROMK in the collecting duct. Because ROMK is also involved in regulating insulin secretion, some Type II patients may have neonatal hyperinsulinemic hypoglycemia.
Type III (CLCNKB, OMIM #607364): short arm of chromosome 1 (1p36.13). Large gene deletions (10–280 kb) between CLCNKB and the immediately adjacent CLCNKA are a common cause, in which case a severe phenotype similar to Type IVb (deficiency of both channels) may be seen. Type III is the most clinically heterogeneous, and phenotypes similar to both NKCC2 or NCCT (Gitelman syndrome) deficiency are possible.
Type IV (BSND, OMIM #602522): short arm of chromosome 1 (1p32.3). Barttin (β-subunit) deficiency causes loss of function of both CLC-Ka and CLC-Kb → severe renal impairment + sensorineural hearing loss. Founder effects reported in the Middle East, particularly in Arab Bedouin villages in northern Israel.
Type V (CASR, OMIM #601199): long arm of chromosome 3 (3q21.1). Dominant activating variants. Understood as a severe form of autosomal dominant hypocalcemia (ADH) accompanied by hypocalcemia + hypomagnesemia + hypocalciuria + a Bartter syndrome phenotype. Caution: symptoms may worsen with administration of cinacalcet (a CaSR agonist).
The genotype-phenotype correlation is relatively clear, so genetic confirmation is important for clinical management and prognostic prediction. Using a next-generation sequencing (NGS)–based tubular disease panel (Bartter/Gitelman panel), the five genes can be analyzed simultaneously.
Bartter syndrome is a rare inherited renal tubular disease with a worldwide incidence estimated at about 1:50,000–100,000 births. However, this figure may be an underestimate considering reporting bias and diagnostic delay. Incidence is equal in males and females, and it occurs in all races.
Regarding frequency by type, Type III (CLCNKB deficiency) is the most common, at 40–50% of all Bartter syndrome, Types I and II each account for 20–25%, and Types IV and V are rare. However, these proportions vary by the population studied, and Type IV in particular has been reported at high frequency in certain populations (Middle Eastern Bedouins).
Accurate incidence data for Bartter syndrome in Korea are limited. Case reports and small cohort studies have been conducted mainly by the Korean Society of Pediatric Nephrology, and the situation can be gauged from rare disease Special Copayment Reduction (V254) registration status, but public data are limited. In Korea, Type III tends to be reported most often, and large deletions within the CLCNKB gene have also been identified in Korean patients.
Gitelman syndrome, which must be differentiated from Bartter syndrome, is estimated to be about 10 times more common than Bartter syndrome (about 1:40,000) and is often found incidentally, mainly in adulthood. Distinguishing the two diseases is clinically important, and in particular classic Bartter syndrome (Type III) can be difficult to differentiate because it shows a clinical phenotype similar to Gitelman syndrome.
By age, Types I and II are the neonatal type (antenatal Bartter syndrome), presenting mainly in the fetal period (polyhydramnios) to the neonatal period; Type III is the classic type, presenting in infancy to childhood; and Type V presents in the neonatal period to early childhood. Type IV is a distinctive type in which the severe neonatal form is accompanied by sensorineural hearing loss.
The core pathophysiology of Bartter syndrome is a cascade of abnormalities stemming from impaired NaCl reabsorption in the thick ascending limb of the loop of Henle (TAL).
Normally, the TAL reabsorbs about 25–30% of the NaCl filtered by the glomerulus. This process begins with the NKCC2 transporter in the apical membrane cotransporting 1Na⁺:1K⁺:2Cl⁻ into the cell. K⁺ that enters the cell is recycled back into the lumen via ROMK channels, maintaining the luminal K⁺ concentration needed for NKCC2 function, and Cl⁻ exits to the interstitium via CLC-Ka and CLC-Kb channels in the basolateral membrane. Na⁺/K⁺-ATPase in the TAL basolateral membrane actively extrudes intracellular Na⁺, providing the driving force.
When NaCl reabsorption is reduced by deficiency of any protein in this pathway, the following cascade occurs.
Impaired NaCl reabsorption in the TAL also impairs urinary concentrating ability, resulting in a diabetes insipidus–like polyuric phenotype. This is because NaCl reabsorption in the TAL is essential for forming the osmotic gradient of the medullary interstitium. Reduced osmotic gradient → reduced action of ADH (vasopressin) in the collecting duct → excretion of large volumes of dilute urine.
Prostaglandin E2 is overproduced mainly in renal tubular and interstitial cells and worsens symptoms through combined mechanisms such as further inhibition of NKCC2 activity, intraglomerular vasodilation, and RAAS stimulation. This is why symptoms improve markedly when PGE2 synthesis is inhibited with indomethacin.
The clinical symptoms of Bartter syndrome vary with the timing of onset and genotype, but tubular electrolyte loss and its secondary consequences are common to all.
Antenatal/neonatal type (mainly Type I, II) — Antenatal Bartter Syndrome
Severe polyhydramnios appears during pregnancy because fetal polyuria increases amniotic fluid turnover. Preterm birth is common, and life-threatening extreme electrolyte abnormalities and dehydration occur immediately after birth. Main neonatal symptoms include polyuria, weight loss, fever, vomiting, lethargy, muscle weakness, and seizures. In Type II, transient hyperkalemia may characteristically occur immediately after birth. Untreated, it can rapidly lead to death from severe dehydration and electrolyte imbalance.
Classic type (mainly Type III) — Classic Bartter Syndrome
Presents relatively gradually over months to years after birth. Main symptoms include failure to thrive, muscle weakness, fatigue, polydipsia and polyuria, salt craving, a tendency to vomit, and constipation. Muscle cramps or spasms may occur, and with severe hypokalemia there is a risk of muscle paralysis and cardiac arrhythmias. Fatigue and poor concentration due to chronic hypokalemia and alkalosis can also affect school life.
Type IV — Barttin deficiency (with sensorineural hearing loss)
In addition to the typical symptoms of neonatal Bartter syndrome, bilateral sensorineural hearing loss appears at birth or early in life. The hearing impairment is severe, and hearing aids or cochlear implantation are often needed. Renal function decline is severe, and chronic kidney disease progresses in infancy to childhood.
Type V — CaSR activating variants
In addition to the Bartter syndrome phenotype (hypokalemia, alkalosis), hypocalcemia is present, causing seizures, tetany, cardiac arrhythmias, and carpopedal spasm. Hypomagnesemia is also observed.
The characteristic objective findings of Bartter syndrome are confirmed through biochemical tests and imaging studies.
Blood biochemistry findings
Urine findings
Imaging findings
Systematic newborn screening for Bartter syndrome is not currently standardized. However, early evaluation in situations of high clinical suspicion and prenatal diagnosis when there is a family history are possible.
Prenatal screening
When unexplained severe polyhydramnios is found during pregnancy, the possibility of fetal polyuria should be considered, and Bartter syndrome is included in the differential diagnosis. Increased renal echogenicity on fetal ultrasound (nephrocalcinosis) and findings suggestive of polyuria may also be observed. In families with an already affected sibling, prenatal confirmation is possible by genetic analysis via CVS or amniocentesis.
Findings raising clinical suspicion in the neonatal period
Bartter syndrome should be suspected immediately if the following findings are present in the neonatal period.
Findings raising suspicion in childhood to adulthood
Bartter syndrome (mainly classic Type III) is considered when hypokalemia and metabolic alkalosis recur together with failure to thrive, muscle weakness, and chronic fatigue, blood pressure is normal, and other causes such as diuretic abuse have been excluded. Genetic testing is essential to differentiate it from Gitelman syndrome.
Family screening
When the diagnosis has been genetically confirmed in siblings of an affected patient, regular electrolyte monitoring is recommended for siblings carrying the same variants, even during asymptomatic periods.
Bartter syndrome is confirmed by integrating clinical and biochemical criteria with molecular genetic testing.
Step 1: clinical and biochemical diagnosis
Step 2: renal imaging
Renal ultrasound or CT: check for nephrocalcinosis, kidney size and echogenicity, and anatomical abnormalities.
Step 3: genetic analysis
NGS-based tubular disease panel including 5 genes (SLC12A1, KCNJ1, CLCNKB, BSND, CASR). Consider whole-exome analysis if negative. For CLCNKB, additional MLPA is recommended to check for large deletions involving the adjacent CLCNKA.
Differential diagnosis
| Disease | Differences from Bartter syndrome |
|---|---|
| Gitelman syndrome (Gitelman, SLC12A3) | Distal convoluted tubule abnormality; hypomagnesemia and hypocalciuria characteristic; mild symptoms in adulthood |
| Diuretic abuse | History and medication review; differentiated by urine diuretic screening |
| Vomiting and laxative abuse (eating disorders) | Differentiated by low urine Cl⁻ (high in Bartter syndrome); history important |
| Secondary hyperaldosteronism (renovascular hypertension) | Blood pressure normal in Bartter syndrome; renovascular hypertension is accompanied by hypertension |
| Liddle syndrome | Characterized by hypertension, low renin, and low aldosterone; the opposite pattern |
The treatment goals of Bartter syndrome are correction of electrolyte abnormalities, symptom improvement, optimization of growth, and protection of renal function. There is still no treatment that corrects the underlying genetic defect, so the focus is on symptom relief and prevention of complications.
Electrolyte supplementation
Potassium supplementation is essential in all types. Oral potassium (KCl) supplementation may require several dozen mEq or more per day, and even with sufficient supplementation it is often difficult to fully normalize serum potassium (the target is 3.0–3.5 mEq/L). When hypomagnesemia is present, magnesium supplementation (magnesium gluconate or magnesium oxide) must be added for hypokalemia to be corrected. In neonates and infants, appropriate intravenous fluid and electrolyte supply must come first.
Indomethacin — key treatment for the neonatal type
Indomethacin, a nonselective COX inhibitor, inhibits PGE2 synthesis and markedly reduces polyuria, dehydration, and potassium loss in neonatal Bartter syndrome (Type I, II), leading to improved growth. The usual dose is 1–3 mg/kg/day (divided three times daily). With long-term use, side effects such as nephrotoxicity (reduced glomerular filtration rate), gastrointestinal side effects, and inhibition of platelet function require attention. Renal function monitoring is needed, and caution is required if renal function is already reduced. In infants, it is usually used after 4 weeks of age. Selective COX-2 inhibitors (celecoxib) are being studied as an alternative because of fewer gastrointestinal side effects.
Renin-angiotensin-aldosterone system (RAAS) blockade
Type IV–specific treatment
In Type IV, along with electrolyte correction, early hearing evaluation and hearing aids, and cochlear implantation, are considered. If renal function progresses to end-stage renal failure, kidney transplantation is needed, and the Bartter syndrome–specific electrolyte abnormalities are corrected after transplantation.
Growth management
Failure to thrive persists if electrolyte correction is insufficient, so the treatment effect is evaluated periodically and doses are adjusted. If growth hormone deficiency is present, growth hormone supplementation may be considered.
The prognosis of Bartter syndrome varies with genotype, timing of diagnosis, and adequacy of treatment. In general, prognosis improves greatly with early diagnosis and appropriate treatment.
Prognosis of the neonatal type (Type I, II)
Before treatment, life-threatening crises due to extreme electrolyte abnormalities recur, but prognosis has improved markedly since the introduction of indomethacin treatment. Over the long term, nephrocalcinosis due to hypercalciuria can lead to renal function decline. Some studies have reported an increased incidence of chronic kidney disease on long-term follow-up. To minimize the progression of nephrocalcinosis, treatments that reduce urinary calcium excretion (indomethacin, addition of a thiazide diuretic) are attempted.
Prognosis of the classic type (Type III)
Overall, the prognosis is better than for the neonatal type. With adequate potassium supplementation, spironolactone, and indomethacin when necessary, growth and daily functioning can be kept close to normal. Nephrocalcinosis is rare or mild. Drug treatment must be continued into adulthood, and special attention to managing electrolyte imbalance is needed during pregnancy.
Prognosis of Type IV
Renal function decline is more marked than in other types, progressing to chronic kidney disease in childhood to young adulthood, and many patients require kidney transplantation. After transplantation the electrolyte abnormalities are corrected, but sensorineural hearing loss persists. Cochlear implantation and rehabilitation can improve language development and quality of life.
Common long-term risks
Chronic hypokalemia causes renal tubular damage (hypokalemic nephropathy) and a risk of cardiac arrhythmias, and over the long term also contributes to glomerular function decline. Ongoing monitoring of renal function (eGFR, proteinuria, blood pressure) and follow-up imaging for nephrocalcinosis are needed. With long-term indomethacin use, monitoring for drug side effects such as nephrotoxicity and gastrointestinal complications is also important.
Prevention of Bartter syndrome is approached as preventing its occurrence (primary prevention), early detection and prevention of acute complications (secondary prevention), and minimizing long-term complications (tertiary prevention).
Primary prevention: genetic counseling and prenatal diagnosis
For families of affected children, especially when both parents are carriers (Type I–IV), genetic counseling explains the recurrence risk (25%) and methods of prenatal diagnosis. Fetal genetic analysis via CVS or amniocentesis is possible. In Type V (autosomal dominant), children of an affected parent have a 50% recurrence risk, and selection of unaffected embryos through preimplantation genetic testing (PGT-M) is also possible. When polyhydramnios is found prenatally, Bartter syndrome is actively investigated to prepare for management of preterm birth and immediate treatment after birth.
Secondary prevention: early diagnosis and prevention of acute electrolyte crises
In neonatal Bartter syndrome, early diagnosis and immediate electrolyte correction are key to preventing serious complications. When there is a family history, electrolyte tests are performed immediately after birth, and early indomethacin administration prevents severe polyuria and dehydration. Patients and caregivers are taught an emergency fluid and electrolyte replacement protocol for use when dehydration, fever, or gastrointestinal symptoms occur.
Tertiary prevention: monitoring of long-term complications
Renal function (eGFR, urine protein/creatinine ratio, blood pressure), nephrocalcinosis (renal ultrasound every 6–12 months), serum electrolytes, and urine calcium/creatinine ratio are followed regularly. In Type IV, hearing function, language development, and cochlear implant function are evaluated regularly. In patients taking long-term indomethacin, worsening renal function and gastrointestinal side effects are monitored (consider adding an acid suppressant to prevent gastric ulcers). In transition to adult care, establishing a multidisciplinary follow-up system centered on a nephrologist is important.
Bartter FC, Pronove P, Gill JR Jr, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. American Journal of Medicine. 1962;33:811–828. DOI: 10.1016/0002-9343(62)90214-0. PMID: 13969763.
Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nature Genetics. 1996;13(2):183–188. DOI: 10.1038/ng0696-183. PMID: 8640224.
Simon DB, Karet FE, Rodriguez-Soriano J, et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nature Genetics. 1996;14(2):152–156. DOI: 10.1038/ng1096-152. PMID: 8841183.
Birkenhäger R, Otto E, Schürmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nature Genetics. 2001;29(3):310–314. DOI: 10.1038/ng752. PMID: 11685209.
Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiology. 2006;104(2):p73–p80. DOI: 10.1159/000094001. PMID: 16714871.
Seys E, Andrini O, Keck M, et al. Clinical and genetic spectrum of Bartter syndrome type 3. Journal of the American Society of Nephrology. 2017;28(8):2540–2552. DOI: 10.1681/ASN.2016101107. PMID: 28373202.
Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney International. 2021;99(2):324–335. DOI: 10.1016/j.kint.2020.10.035. PMID: 33160010.
Fremont OT, Chan JCM. Understanding Bartter syndrome and Gitelman syndrome. World Journal of Pediatrics. 2012;8(1):25–30. DOI: 10.1007/s12519-012-0340-4. PMID: 22282139.
Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2017;91(1):24–33. DOI: 10.1016/j.kint.2016.09.046. PMID: 27884312.
Jeck N, Schlingmann KP, Reinalter SC, et al. Salt handling in the distal nephron: lessons learned from inherited human disorders. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2005;288(4):R782–R795. DOI: 10.1152/ajpregu.00600.2004. PMID: 15761185.